COMMON GENOTYPES AND TREATMENT OUTCOMES OF HCV INFECTION AMONG ETHIOPIAN PATIENTS: A PROSPECTIVE STUDY

Endale Kassa | Bio
Addis Ababa University
Abate Bane | Bio
Addis Ababa University, Medical faculty, Department of Internal Medicine, Addis Ababa, Ethiopia
Hailu Kefene
Old Airport Higher clinic
Share:
  • Articles
  • Submited: September 30, 2015
  • Published: January 14, 2016

Abstract

Background: The treatment response of HCV infection is dependent on genotype and stage of the disease. However, genotype pattern and treatment outcomes of HCV infection among Ethiopian patients has not been studied so far.

Objectives: To evaluate the common HCV genotypes and treatment outcomes among Ethiopian adult patients.

Method: Adult patients aged 18 and above with HCV infection referred from various regions of the country were included in the study after written informed consent. As there was no free or insurance coverage for treatment of HCV infection in the country, those who could afford to pay for treatment with PEG Interferon and Ribavirin were recruited during January 1, 2008 through December 31,2013 at United Vision, Adera, Old Airport, and Mexico referral higher clinics in Addis Ababa. Patients with decompensated cirrhosis and pregnant ladies were excluded from the study. The patients were counseled on treatment options, cost, treatment outcomes, adverse drug effects, and possible complications. Data were collected on demographic features, clinical characteristics, viral genotypes, and treatment outcomes during follow up visits until six months after completion of recommended standard treatment. Data were analyzed using SPSS software.

Results: A total of 200 adults with chronic HCV infection were treated with PEG -Interferon and Ribavirin (for 24 or 48 weeks according to the genotypes) during the study period. Of the 200 patients enrolled in the study, 120(60%) were male, 90% were from Addis Ababa, and the median age was 48 years. Sixty per cent of the patients were infected with genotype 4,17% with genotype 1, 13.5% with genotype 2 and 9.5% with genotype 3.

Eighty percent of the patients had end of treatment response; of these, 74.4% had undetectable HCV RNA at6th month after end of treatment. The end of treatment response was noted to be close to 90% for patients with HCV genotypes 2 and 3 infections.

Conclusion: This study indicates that genotype 4 is the prevalent HCV genotype followed by 1,2, and 3 among Ethiopian patients. Treatment with interferon and ribavirin was well tolerated and provided a very good response.

Key words: HCV, genotypes, treatment, Ethiopia.

 

Downloads

Download data is not yet available.

References

  1. Madhava, V., Burgess, C. & Drucker, E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2012 (2): 293-302.
  2. Perz, J. F., Armstrong, G. L., Farrington, L. A., et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 (45): 529-38.
  3. Mohd Hanafiah, K., Groeger, J., Flaxman, A. D. et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013 (57): 1333-342.
  4. Gower, E., Estes, C., Blach, S., et al Causes of death in HIV-1-infected patients treated with antiretroviral therapy: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010 (50) :1387-396.
  5. Razavi, H., Elkhoury, A. C., Elbasha, E., et al Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013(57): 2164-170.
  6. Timm, J. & Roggendorf, M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol 2007 (13): 4808-817.
  7. Simmonds, P., Alberti, A., Alter, H. J., et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994 (19): 1321-324.
  8. Simmonds, P. The origin and evolution of hepatitis viruses in humans. J Gen Virol 2001 (82): 693-712.
  9. Magiorkinis, G., Magiorkinis, E., Paraskevis, D, et al The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med 2009 (6): e1000198.
  10. Pybus, O. G. & Barnes, E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015 (61): 77-87.
  11. Murphy, D. G., Willems, B., Deschenes, M., et al. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol 2007 (45): 1102-112.
  12. Markov, P. V., van de Laar, T. J., Thomas, X, et al. Colonial history and contemporary transmission shape the genetic diversity of hepatitis C virus genotype 2 in Amsterdam. J Virol 2012 (86): 7677-87
  13. Abera, B., Zenebe, Y., Mulu, W., et al. Seroprevalence of hepatitis B and C viruses and risk factors in HIV infected children at the felgehiwot referral hospital, Ethiopia. BMC Res Notes 2014 (7): 838.
  14. Ayele, W., Nokes, D. J., Abebe, A., et al. Higher prevalence of anti-HCV antibodies among HIV-positive compared to HIV-negative inhabitants of Addis Ababa, Ethiopia. J Med Virol 2002 (68): 12-17.
  15. Lauer, G. M. & Walker, B. D. Hepatitis C virus infection. N Engl J Med 2001(345): 41-52.
  16. Abreha, T., Woldeamanuel, Y., Pietsch, C., et al. Genotypes and viral load of hepatitis C virus among persons attending a voluntary counseling and testing center in Ethiopia. J Med Virol 2011 (83): 776-82.
  17. Taye, S., Abdulkerim, A. & Hussen, M. Prevalence of hepatitis B and C virus infections among patients with chronic hepatitis at Bereka Medical Center, Southeast Ethiopia: a retrospective study. BMC Res Notes 2014 (7): 272.
  18. Messina JP1, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87.
  19. Pybus, O. G., Cochrane, A., Holmes, E. C. & Simmonds.Genotype Distribution of Hepatitis C Virus in Satildeo Paulo, BrazilHepatology, 1999 (29):994-95
  20. Mercy Jelagat Karoney, Abraham Mosigisi Siika. Hepatitis C virus (HCV) infection in Africa: a review. The Pan African Medical Journal. http://www.panafrican-med- doi:10.11604/pamj.2013(14) 44.2199
  21. Smith, D. B., Pathirana, S., Davidson, F., et al. The origin of hepatitis C virus genotypes. J Gen Virol 78 ,1997 (Pt 2), 321-28.
  22. Taye, S. & Lakew, M. Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia. BMC Immunol 2013(14): 23-26.
  23. Shepard, C. W., Finelli, L. & Alter, M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis2005(5): 558-67.
  24. Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. & Razavi, H. Global epidemiology and genotype distribution of the hepatitis C virus infection. (2014) J Hepatol 2014(61): S45-S57.
  25. Nizar N. Zein. Clinical Significance of Hepatitis C Virus Genotypes. Clin Microbiol Rev. 2000;13(2): 223–35.
How to Cite
Kassa, E., Bane, A., & Kefene, H. (2016). COMMON GENOTYPES AND TREATMENT OUTCOMES OF HCV INFECTION AMONG ETHIOPIAN PATIENTS: A PROSPECTIVE STUDY. Ethiopian Medical Journal, 54(1). Retrieved from https://emjema.org/index.php/EMJ/article/view/203

Send mail to Author


Send Cancel